Is Haemonetics Corporation (HAE) overvalued? · P/E 35, rev $1.36B
Haemonetics Corporation (HAE) is a medical devices company listed on US.
This page asks whether Haemonetics Corporation (HAE) looks expensive on cached numbers — not a short thesis.
Latest reported HAE revenue for 2025-03-29 was $1.36B. Net income was $167.7M. Revenue was up 4.0% from 2024-03-30 to 2025-03-29. HAE currently screens at market cap $3.24B and trailing P/E 34.8.
HAE currently screens at market cap $3.24B and trailing P/E 34.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next HAE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the HAE stock page for the full model, not this heading.
Not investment advice.